Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

PURPOSE: Locally advanced or metastatic urothelial carcinoma is an incurable disease with limited treatment options, especially for patients who were previously treated with platinum and anti–programmed death 1 or anti–programmed death ligand 1 (PD-1/L1) therapy. Enfortumab vedotin is an antibody–dr...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Rosenberg, Jonathan E., O’Donnell, Peter H., Balar, Arjun V., McGregor, Bradley A., Heath, Elisabeth I., Yu, Evan Y., Galsky, Matthew D., Hahn, Noah M., Gartner, Elaina M., Pinelli, Juan M., Liang, Shang-Ying, Melhem-Bertrandt, Amal, Petrylak, Daniel P.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2019
Témata:
RAPID COMMUNICATION
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6784850/
https://ncbi.nlm.nih.gov/pubmed/31356140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01140
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky